Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H, Masquelier B. da Silva D, et al. Among authors: reigadas s. J Antimicrob Chemother. 2010 Jun;65(6):1262-9. doi: 10.1093/jac/dkq099. Epub 2010 Apr 12. J Antimicrob Chemother. 2010. PMID: 20388636
Structure-analysis of the HIV-1 integrase Y143C/R raltegravir resistance mutation in association with the secondary mutation T97A.
Reigadas S, Masquelier B, Calmels C, Laguerre M, Lazaro E, Vandenhende M, Neau D, Fleury H, Andréola ML. Reigadas S, et al. Antimicrob Agents Chemother. 2011 Jul;55(7):3187-94. doi: 10.1128/AAC.00071-11. Epub 2011 May 16. Antimicrob Agents Chemother. 2011. PMID: 21576445 Free PMC article.
The HIV-1 integrase (IN) mutations Y143C/R are known as raltegravir (RAL) primary resistance mutations. In a previous study (S. Reigadas et al., PLoS One 5:e10311, 2010), we investigated the genetic pathway and the dynamics of emergence of the Y143C/R mutations in t …
The HIV-1 integrase (IN) mutations Y143C/R are known as raltegravir (RAL) primary resistance mutations. In a previous study (S. Re …
HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.
Reigadas S, Marcelin AG, Houssaïni A, Yerly S, Descamps D, Plantier JC, Ruffault A, Amiel C, Trabaud MA, Flandre P, Fleury H, Masquelier B; ANRS AC11 Resistance Study Group. Reigadas S, et al. J Antimicrob Chemother. 2013 Apr;68(4):969-72. doi: 10.1093/jac/dks474. Epub 2012 Nov 25. J Antimicrob Chemother. 2013. PMID: 23184711 No abstract available.
Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure.
Vandenhende MA, Bellecave P, Recordon-Pinson P, Reigadas S, Bidet Y, Bruyand M, Bonnet F, Lazaro E, Neau D, Fleury H, Dabis F, Morlat P, Masquelier B. Vandenhende MA, et al. Among authors: reigadas s. PLoS One. 2014 Jan 27;9(1):e86771. doi: 10.1371/journal.pone.0086771. eCollection 2014. PLoS One. 2014. PMID: 24475178 Free PMC article.
TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality.
Efsen AM, Panteleev AM, Grint D, Podlekareva DN, Vassilenko A, Rakhmanova A, Zeltina I, Losso MH, Miller RF, Girardi E, Caylá J, Post FA, Miro JM, Bruyand M, Furrer H, Obel N, Lundgren JD, Mocroft A, Kirk O; HIV/TB Study Group. Efsen AM, et al. Biomed Res Int. 2013;2013:373601. doi: 10.1155/2013/373601. Epub 2013 Dec 31. Biomed Res Int. 2013. PMID: 24699884 Free PMC article.
73 results